Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

Multiple Cancer Types

This phase II trial studies how well pemigatinib works in treating patients with colorectal cancer with mutations (alterations) in a FGFR gene and that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Pemigatinib may stop the growth of tumor cells by blocking FGFR, which is needed for cell growth.
Colon, Rectal
II
Ciombor, Kristen
NCT04096417
VICCGI2028

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: